Neko Health raises $700 million to bring full-body scan clinics to the US
Money MovesDaniel Ek's preventive-care startup hits a roughly $7 billion valuation and plans its first American clinic in New York
July 15th, 2026: Neko raises $700 million for US launchNew here? Follow stories to track developments over time. Create a free account to get updates when stories you care about change.
Overview
Neko Health just raised $700 million, one of the largest single funding rounds the preventive-health field has seen. The Swedish company, co-founded by Spotify's Daniel Ek, will use the money to open its first US clinic in New York.
Neko sells a 60-minute full-body scan meant to catch disease before symptoms appear. More than 100,000 people have been scanned in Sweden and the UK, and over 300,000 more are on a US waitlist. The round values the company at about $7 billion, roughly four times its worth 18 months ago.
Why it matters
If Neko's model works, catching disease early could shift from a doctor's referral to a $300 scan you book like a dentist appointment.
Questions about this story
No questions yet — be the first to ask.
Key Indicators
Voices
Curated perspectives — historical figures and your fellow readers.
Play
Exploring all sides of a story is often best achieved with Play.
Higher or Lower
A number from this story, against one from elsewhere in the news — guess which is bigger, then keep the chain going. 5 rounds, 3 strikes; a miss costs a strike and resets your streak.
Keyboard: ↓/L lower · ↑/H higher
0 points — sign up to put that on the leaderboard.
Connections
Sixteen names from the news. Find the four hidden groups of four. Four mistakes max.
Sign up to keep a daily streak — a new puzzle lands every day.
Exit debate?
Your progress in this debate will be lost.
- 1 Two AI personas square off on this story.
- 2 You predict who'll win each round — correct picks earn XP.
- 3 One crossfire question is yours to fire. Pick it carefully.
Couldn't generate a topic
Select Your Champions
Choose one persona for each side of the debate
DEBATE TOPIC
Choose personas with different perspectives for a more dynamic debate.
Select debater for this side:
No debate personas available right now.
Select debater for this side:
No debate personas available right now.
Who's Got This Round?
Make your prediction before the referee scores
The referee scores both sides on
Round Results
Set the Crossfire
Pick the question both personas must answer in the final round
Debate Oracle! You called every round!
Sharp Instincts! You know your debaters!
The Coin Flip Strategist! Perfectly balanced!
The Contrarian! Bold predictions!
Inverse Genius! Try betting the opposite next time!
XP Breakdown
Prediction History
People Involved
Organizations Involved
A Swedish company that runs clinics offering a 60-minute full-body health scan built to catch disease early.
A large US venture firm that led Neko's $700 million round.
Timeline
January 2018 July 2026
-
Neko raises $700 million for US launch
Latest FundingThe Series C values Neko near $7 billion and funds its first US clinic in New York.
-
Series B raises $260 million
FundingThe round values Neko at roughly $1.8 billion as it expands into the UK.
-
First clinic opens in Stockholm
MilestoneNeko begins offering its 60-minute full-body scan to the public in Sweden.
-
Neko Health founded
FoundingDaniel Ek and Hjalmar Nilsonne start Neko to catch disease before symptoms appear.
Historical Context
3 moments from history that rhyme with this story — and how they unfolded.
Theranos collapse (2018)
Theranos claimed its machines could run hundreds of tests from a single drop of blood. Investigations found the technology did not work as promised. Founder Elizabeth Holmes was later convicted of fraud.
The company dissolved in 2018 and investors lost roughly $700 million.
It made investors and regulators far more skeptical of health startups that promise breakthrough diagnostics without published evidence.
Neko sells consumer diagnostics on a bold promise too. The Theranos memory raises the bar for proof that its scans actually improve health outcomes.
23andMe rise and fall (2007-2025)
23andMe sold at-home DNA kits that gave consumers health and ancestry data. It reached a multibillion-dollar valuation, then struggled to turn one-time tests into lasting revenue and filed for bankruptcy in 2025.
The company's value collapsed from a peak near $6 billion.
It showed that consumer health data is easy to sell once but hard to build a durable business around.
Neko faces the same question: can a one-time scan become a repeat relationship, or will customers scan once and not return?
Whole-body MRI screening debate (2024-2026)
US firms like Prenuvo and Ezra scanned tens of thousands of healthy people with MRI. Medical reviews warned of frequent false positives and no proven survival benefit, while the companies defended the scans' value.
The companies kept growing despite the criticism.
The dispute over screening healthy people remains unsettled, with no clear regulatory ruling.
Neko enters a US market already arguing about whether scanning the healthy helps or harms. It will inherit that debate on day one.
